Pmv Pharmaceuticals Inc (PMVP) Stock Price, Quote & News

Company Profile

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmace...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 642 6670

Website: www.pmvpharma.com

Address:

400 Alexander Park Drive, Suite 301, Princeton, United States

StockScanners Feb. 28 at 7:15 PM

$PMVP keep watch if this holds above 1.65

0 · Reply

GangsterX Feb. 27 at 8:57 PM

$ALLO $PMVP What did I say????

0 · Reply

Sawnchey Feb. 27 at 8:51 PM

$PMVP Good to see this company finally getting some appreciation from the markets! A long way to go still to reach its real value though!

0 · Reply

justiceforb_85 Feb. 27 at 7:17 PM

$PMVP still trading below cash.

0 · Reply

GangsterX Feb. 27 at 6:08 PM

$PMVP $ALLO $GERN What did I say??? i called pmvp when it was 1.04. I keep saying pmvp will be next before Big pop in the history. Never listen... still holding both. Gern will be next.. will get in gern next week

0 · Reply

StormSurgeX Feb. 27 at 6:07 PM

\@SqueezeSharkie is operating at a level that clearly sets him apart from most traders in this space. If you’re serious about improving your decision-making and refining your edge, he’s worth following. There’s no cost, just consistent insights backed by performance. $PMVP $MMA $STRZ $RLAY || on watch as well

1 · Reply

Mega_Moons Feb. 27 at 5:59 PM

Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥 $ROOT $TRIP $TNXP $PMVP Solid

0 · Reply

Mega_Moons Feb. 27 at 5:57 PM

Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥. $LUMN $DNOW $PMVP $SRFM good.

0 · Reply

GangsterX Feb. 27 at 4:54 PM

$PMVP $ALLO $GERN I nailed all my favorite picks with big bet like crazy.. I will buy Gern next week. I am still holding pmvp and allo. Never sell. Gern will be my next bet....

0 · Reply

Sabini Feb. 27 at 3:47 PM

$PMVP Market cap of 80M... Curious what they will do funding wise to proceed in phase II but feedback to their phase I presentation and now publication was super positive. This clearly has potential for a multi tenbagger if everythings goes well in the next years.

0 · Reply

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Oct 13, 2025, 4:01 PM EDT - 4 months ago

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 10, 2025, 3:10 PM EDT - 6 months ago

Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

Sep 10, 2025, 7:00 AM EDT - 6 months ago

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Aug 7, 2025, 8:42 AM EDT - 7 months ago

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

May 23, 2025, 4:05 PM EDT - 10 months ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

Mar 3, 2025, 8:00 AM EST - 1 year ago

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

May 29, 2024, 7:00 AM EDT - 1 year ago

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

May 9, 2024, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

Mar 27, 2024, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

Mar 18, 2024, 4:01 PM EDT - 2 years ago

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

Feb 29, 2024, 4:01 PM EST - 2 years ago

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

Jan 18, 2024, 4:01 PM EST - 2 years ago

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

Jan 5, 2024, 4:01 PM EST - 2 years ago

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

Nov 14, 2023, 6:50 PM EST - 2 years ago

PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price

Nov 9, 2023, 8:00 AM EST - 2 years ago

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

Oct 12, 2023, 12:30 PM EDT - 2 years ago

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

Oct 11, 2023, 12:00 PM EDT - 2 years ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

Sep 20, 2023, 4:05 PM EDT - 2 years ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 30, 2023, 9:20 AM EDT - 2 years ago

PMV Pharmaceuticals: A 5-Month Run-Up Is Justified

Aug 9, 2023, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

Jun 6, 2023, 4:01 PM EDT - 2 years ago

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

May 10, 2023, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

Mar 1, 2023, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

Feb 28, 2023, 4:05 PM EST - 3 years ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

Nov 22, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Nov 8, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

Nov 4, 2022, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

Aug 9, 2022, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

Jul 18, 2022, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Jun 7, 2022, 12:00 PM EDT - 4 years ago

PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

May 26, 2022, 5:05 PM EDT - 4 years ago

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 10, 2022, 7:30 AM EDT - 4 years ago

PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights

Apr 27, 2022, 10:30 AM EDT - 4 years ago

PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 1, 2022, 7:15 AM EST - 4 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Feb 28, 2022, 8:00 AM EST - 4 years ago

PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference

Feb 3, 2022, 8:00 AM EST - 4 years ago

PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day

Jan 6, 2022, 8:00 AM EST - 4 years ago

PMV Pharma Announces Changes to its Board of Directors

Nov 22, 2021, 8:00 AM EST - 4 years ago

PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference

Nov 12, 2021, 7:15 AM EST - 4 years ago

PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

Sep 2, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Aug 13, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

Jun 9, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

May 14, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

May 5, 2021, 8:00 AM EDT - 5 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

Apr 10, 2021, 1:31 PM EDT - 5 years ago

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021

Apr 6, 2021, 8:00 AM EDT - 5 years ago

PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum

Mar 10, 2021, 4:31 PM EST - 5 years ago

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Mar 3, 2021, 4:01 PM EST - 5 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Feb 16, 2021, 8:00 AM EST - 5 years ago

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

StockScanners Feb. 28 at 7:15 PM

$PMVP keep watch if this holds above 1.65

0 · Reply

GangsterX Feb. 27 at 8:57 PM

$ALLO $PMVP What did I say????

0 · Reply

Sawnchey Feb. 27 at 8:51 PM

$PMVP Good to see this company finally getting some appreciation from the markets! A long way to go still to reach its real value though!

0 · Reply

justiceforb_85 Feb. 27 at 7:17 PM

$PMVP still trading below cash.

0 · Reply

GangsterX Feb. 27 at 6:08 PM

0 · Reply

StormSurgeX Feb. 27 at 6:07 PM

1 · Reply

Mega_Moons Feb. 27 at 5:59 PM

Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥 $ROOT $TRIP $TNXP $PMVP Solid

0 · Reply

Mega_Moons Feb. 27 at 5:57 PM

Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥. $LUMN $DNOW $PMVP $SRFM good.

0 · Reply

GangsterX Feb. 27 at 4:54 PM

$PMVP $ALLO $GERN I nailed all my favorite picks with big bet like crazy.. I will buy Gern next week. I am still holding pmvp and allo. Never sell. Gern will be my next bet....

0 · Reply

Sabini Feb. 27 at 3:47 PM

0 · Reply

GangsterX Feb. 27 at 2:50 PM

$PMVP $ALLO Never sell... No need to thank me baby.. Enjoy big $$

0 · Reply

GangsterX Feb. 26 at 9:58 PM

$GERN $ALLO $PMVP My big $$ will put into gern next week. Watch and Learn how Master makes $$$ like Allo and pmvp. I am holding both and didd not sell shix...

0 · Reply

GangsterX Feb. 26 at 8:11 PM

$PMVP Dont expext this stock to run hard right now. It is up and down for months until Summer. But it will move up to 2. Just HOLd

0 · Reply

justiceforb_85 Feb. 26 at 7:36 PM

$PMVP $XBI awesome movement but still trading below cash for a drug that would address those with TP53 Y220C mutations (best data in ovarian).

0 · Reply

hbkstockislife Feb. 26 at 7:25 PM

$PMVP did they cure cancer or what

1 · Reply

GangsterX Feb. 26 at 7:06 PM

$PMVP $ALLO Here we goo

0 · Reply

prismmarketview Feb. 26 at 5:30 PM

PMV Pharmaceuticals (NASDAQ: $PMVP) published first-in-human Phase 1 data for p53 reactivator rezatapopt in the New England Journal of Medicine, showing antitumor activity and tolerability in 77 heavily pretreated TP53 Y220C-mutant solid tumor patients and supporting a registrational Phase 2 strategy and planned 2027 NDA in platinum-resistant ovarian cancer. https://prismmarketview.com/pmv-pharma-publishes-first-in-human-rezatapopt-data-in-new-england-journal-of-medicine/

0 · Reply

GangsterX Feb. 26 at 3:54 PM

$PMVP $ALLO When the thumb goes up, Just like that baby

1 · Reply

GangsterX Feb. 26 at 3:53 PM

$ALLO $PMVP What did I say??? If i am here, nothing to worry... u know me... if i nail something, it has to be right

0 · Reply

Stock_Catcher Feb. 26 at 1:36 PM

$PMVP PMVP New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

0 · Reply

justiceforb_85 Feb. 26 at 5:17 AM

$PMVP this seems incredibly undervalued based on the data presented thus far for TP53 Y220C mutated cancers. https://www.nejm.org/doi/full/10.1056/NEJMoa2508820?query=featured_home

0 · Reply

GangsterX Feb. 25 at 8:06 PM

$PMVP $ALLO Oh mama yaaaa!! Heooloooooooo $$$$$ babyyyy

0 · Reply

Market Cap	72.90M
Revenue (ttm)	0.00
Net Income (ttm)	-58.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,804,000
Avg Vol	377,356
Day's Range	N/A - N/A
Shares Out	53.21M
Stochastic %K	99%
Beta	1.39
Analysts	Strong Sell
Price Target	$5.50